In conclusion, this network meta‐analysis reinforces SGLT2 inhibitors as the most reliable therapy for renal protection in patients with T2DM and CKD, while GLP‐1 receptor agonists provide additional but variable benefits, and DPP‐4 inhibitors show no effect. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.